St. Jude, Scripps Research Institute, and others launch Dark Proteome Initiative

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ST. JUDE CHILDREN’S RESEARCH HOSPITAL, The Scripps Research Institute and other institutions launched the Human Dark Proteome Initiative, to focus on the portion of the proteome that does not adopt defined 3D structures.

Recent developments in technology, including advances in nuclear magnetic resonance spectroscopy methods, allow researchers to study intrinsically disordered proteins and intrinsically disordered regions of these molecules.

“Our goal is to raise awareness about the potential societal impacts of a broad-based research infrastructure for these understudied proteins,” said Richard Kriwacki, a member of the St. Jude Department of Structural Biology.

YOU MAY BE INTERESTED IN

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login